国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2012年
8期
601-604
,共4页
癌,非小细胞肺%受体,表皮生长因子%酶抑制剂
癌,非小細胞肺%受體,錶皮生長因子%酶抑製劑
암,비소세포폐%수체,표피생장인자%매억제제
Carcinoma,non-small-cell lung%Receptor,epidermal growth factor%Enzyme inhibitors
表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)是一类高效低毒的抗肿瘤分子靶向药物,因其独特的疗效和良好的耐受性在非小细胞肺癌(NSCLC)治疗中成为研究的热点,在NSCLC的一线、二线或三线的辅助治疗中均有一定地位.随着研究的深入细化,EGFR-TKI的适应证不断扩大,术前新辅助治疗可能成为一种新的治疗模式.
錶皮生長因子受體酪氨痠激酶抑製劑(EGFR-TKI)是一類高效低毒的抗腫瘤分子靶嚮藥物,因其獨特的療效和良好的耐受性在非小細胞肺癌(NSCLC)治療中成為研究的熱點,在NSCLC的一線、二線或三線的輔助治療中均有一定地位.隨著研究的深入細化,EGFR-TKI的適應證不斷擴大,術前新輔助治療可能成為一種新的治療模式.
표피생장인자수체락안산격매억제제(EGFR-TKI)시일류고효저독적항종류분자파향약물,인기독특적료효화량호적내수성재비소세포폐암(NSCLC)치료중성위연구적열점,재NSCLC적일선、이선혹삼선적보조치료중균유일정지위.수착연구적심입세화,EGFR-TKI적괄응증불단확대,술전신보조치료가능성위일충신적치료모식.
The epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)is a kind of high-efficiency and low-toxicity tumor molecular targeted drugs.It becomes a research hotspot in non-small cell lung cancer (NSCLC)treatment because of its unique curative effect and well tolerance.EGFR-TKI is mainly applied to the second and third line treatment of patients with advanced NSCLC or first line treatment of EGFR mutation patients.With the development of research,the indications of EGFR-TKI expand unceasingly.The preoperative neoadjuvant therapy is likely to become a new kind of treatment mode.
